Martin McCarter
Concepts (810)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 52 | 2025 | 764 | 7.680 |
Why?
| | Esophageal Neoplasms | 29 | 2025 | 351 | 5.030 |
Why?
| | Skin Neoplasms | 34 | 2024 | 805 | 4.530 |
Why?
| | Adenocarcinoma | 29 | 2025 | 927 | 3.270 |
Why?
| | Esophagectomy | 20 | 2024 | 136 | 3.260 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 77 | 2.540 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 117 | 2.520 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 41 | 2.060 |
Why?
| | Neoadjuvant Therapy | 15 | 2025 | 474 | 1.610 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 49 | 1.590 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 159 | 1.570 |
Why?
| | Dendritic Cells | 13 | 2019 | 507 | 1.530 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 411 | 1.500 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 944 | 1.490 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 1156 | 1.430 |
Why?
| | Stomach Neoplasms | 6 | 2025 | 128 | 1.360 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 335 | 1.280 |
Why?
| | Neoplasm Staging | 33 | 2025 | 1486 | 1.250 |
Why?
| | Tumor Escape | 4 | 2017 | 50 | 1.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1996 | 1.100 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 119 | 1.070 |
Why?
| | Humans | 218 | 2026 | 145625 | 1.060 |
Why?
| | Sarcoma | 8 | 2026 | 209 | 1.060 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 257 | 1.050 |
Why?
| | HIV-1 | 17 | 2025 | 911 | 1.040 |
Why?
| | Lymph Nodes | 15 | 2023 | 511 | 1.030 |
Why?
| | Middle Aged | 107 | 2026 | 36359 | 1.020 |
Why?
| | Anus Neoplasms | 3 | 2024 | 33 | 1.010 |
Why?
| | Neoplasms | 14 | 2025 | 2944 | 1.000 |
Why?
| | Aged | 89 | 2026 | 26251 | 0.980 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 102 | 0.950 |
Why?
| | Hyperglycemia | 3 | 2020 | 381 | 0.930 |
Why?
| | Retrospective Studies | 57 | 2026 | 17291 | 0.930 |
Why?
| | Postoperative Complications | 21 | 2025 | 2962 | 0.930 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 31 | 0.930 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 69 | 0.910 |
Why?
| | HIV Infections | 21 | 2025 | 3210 | 0.880 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1148 | 0.880 |
Why?
| | Prognosis | 30 | 2025 | 4331 | 0.880 |
Why?
| | Laparoscopy | 8 | 2024 | 474 | 0.870 |
Why?
| | Colorectal Neoplasms | 8 | 2025 | 870 | 0.860 |
Why?
| | Intestine, Small | 2 | 2024 | 160 | 0.830 |
Why?
| | Survival Rate | 23 | 2025 | 2078 | 0.820 |
Why?
| | Male | 121 | 2026 | 73014 | 0.810 |
Why?
| | Female | 132 | 2026 | 79080 | 0.800 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 39 | 0.790 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 666 | 0.770 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 149 | 0.730 |
Why?
| | Lymph Node Excision | 8 | 2022 | 173 | 0.720 |
Why?
| | Tretinoin | 3 | 2023 | 114 | 0.720 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 103 | 0.700 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1136 | 0.680 |
Why?
| | T-Lymphocytes | 8 | 2024 | 2007 | 0.680 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 12 | 0.660 |
Why?
| | Gastrointestinal Microbiome | 9 | 2025 | 767 | 0.650 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 73 | 0.650 |
Why?
| | Radiosurgery | 4 | 2020 | 398 | 0.620 |
Why?
| | Anastomotic Leak | 4 | 2024 | 45 | 0.620 |
Why?
| | Adult | 69 | 2026 | 40821 | 0.620 |
Why?
| | Survival Analysis | 16 | 2022 | 1372 | 0.610 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.610 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 238 | 0.600 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 50 | 0.590 |
Why?
| | Piperazines | 5 | 2014 | 367 | 0.580 |
Why?
| | Ipilimumab | 2 | 2019 | 44 | 0.580 |
Why?
| | Myeloid Cells | 3 | 2020 | 149 | 0.570 |
Why?
| | Spleen | 6 | 2017 | 503 | 0.570 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 47 | 0.570 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 143 | 0.550 |
Why?
| | Granulocytes | 2 | 2017 | 82 | 0.550 |
Why?
| | Pyrimidines | 5 | 2014 | 530 | 0.540 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 87 | 0.530 |
Why?
| | Monocytes | 2 | 2020 | 538 | 0.530 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 585 | 0.530 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 28 | 0.520 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2218 | 0.520 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1269 | 0.500 |
Why?
| | Aged, 80 and over | 28 | 2024 | 8351 | 0.500 |
Why?
| | Pylorus | 1 | 2017 | 17 | 0.500 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.500 |
Why?
| | Follow-Up Studies | 20 | 2025 | 5397 | 0.490 |
Why?
| | Mucous Membrane | 5 | 2024 | 129 | 0.490 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 929 | 0.490 |
Why?
| | Time-to-Treatment | 4 | 2025 | 257 | 0.480 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 46 | 0.470 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 133 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 200 | 0.460 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 60 | 0.460 |
Why?
| | Treatment Outcome | 29 | 2026 | 11744 | 0.460 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 563 | 0.460 |
Why?
| | Leucovorin | 2 | 2019 | 98 | 0.460 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 155 | 0.440 |
Why?
| | Liver Neoplasms | 6 | 2024 | 774 | 0.440 |
Why?
| | Vitamin B Complex | 1 | 2014 | 39 | 0.420 |
Why?
| | Immune Tolerance | 4 | 2016 | 384 | 0.410 |
Why?
| | Lymphocytes | 3 | 2021 | 379 | 0.400 |
Why?
| | Salvage Therapy | 2 | 2014 | 163 | 0.400 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 54 | 0.400 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 192 | 0.400 |
Why?
| | Pancreatectomy | 5 | 2024 | 289 | 0.390 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 106 | 0.390 |
Why?
| | Pelvis | 1 | 2014 | 129 | 0.390 |
Why?
| | Ear, External | 1 | 2013 | 22 | 0.390 |
Why?
| | Mohs Surgery | 1 | 2013 | 30 | 0.380 |
Why?
| | Up-Regulation | 5 | 2025 | 840 | 0.380 |
Why?
| | Mutation | 9 | 2025 | 4082 | 0.380 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 127 | 0.370 |
Why?
| | Microbiota | 5 | 2024 | 724 | 0.370 |
Why?
| | Immunity, Innate | 5 | 2025 | 843 | 0.370 |
Why?
| | B-Lymphocytes | 4 | 2025 | 884 | 0.370 |
Why?
| | Biopsy | 3 | 2023 | 1073 | 0.370 |
Why?
| | Abdominal Neoplasms | 3 | 2025 | 48 | 0.360 |
Why?
| | Prospective Studies | 22 | 2025 | 8087 | 0.360 |
Why?
| | Retroperitoneal Neoplasms | 4 | 2026 | 27 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 627 | 0.350 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 745 | 0.350 |
Why?
| | Hematologic Diseases | 1 | 2012 | 66 | 0.350 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 161 | 0.350 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.350 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1334 | 0.340 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 59 | 0.340 |
Why?
| | Cytokines | 8 | 2021 | 2079 | 0.340 |
Why?
| | Cell Movement | 6 | 2025 | 950 | 0.330 |
Why?
| | Dasatinib | 2 | 2024 | 58 | 0.330 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 331 | 0.330 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 22 | 0.310 |
Why?
| | Palliative Care | 1 | 2019 | 1032 | 0.310 |
Why?
| | Thrombelastography | 2 | 2024 | 181 | 0.310 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 481 | 0.310 |
Why?
| | Granzymes | 2 | 2021 | 51 | 0.310 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 29 | 0.300 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 133 | 0.300 |
Why?
| | Benzamides | 5 | 2014 | 226 | 0.300 |
Why?
| | Homosexuality, Male | 3 | 2021 | 231 | 0.300 |
Why?
| | Databases, Factual | 7 | 2025 | 1481 | 0.300 |
Why?
| | Young Adult | 20 | 2025 | 14240 | 0.300 |
Why?
| | Interferon-gamma | 6 | 2019 | 780 | 0.300 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 15 | 0.290 |
Why?
| | Immunotherapy | 5 | 2024 | 669 | 0.280 |
Why?
| | Butyrates | 2 | 2021 | 65 | 0.280 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 495 | 0.280 |
Why?
| | Interleukin-15 | 2 | 2021 | 96 | 0.280 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 97 | 0.270 |
Why?
| | Medical Oncology | 4 | 2022 | 344 | 0.270 |
Why?
| | Barrett Esophagus | 3 | 2020 | 172 | 0.270 |
Why?
| | Cell Differentiation | 5 | 2016 | 1979 | 0.270 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 693 | 0.270 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 429 | 0.270 |
Why?
| | Wounds and Injuries | 4 | 2009 | 956 | 0.270 |
Why?
| | Interleukin-10 | 4 | 2025 | 310 | 0.270 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 271 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2018 | 507 | 0.260 |
Why?
| | Blood Preservation | 2 | 2009 | 346 | 0.260 |
Why?
| | Disease-Free Survival | 8 | 2019 | 777 | 0.260 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 972 | 0.250 |
Why?
| | Nomograms | 2 | 2019 | 59 | 0.250 |
Why?
| | General Surgery | 2 | 2007 | 203 | 0.250 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 14 | 0.250 |
Why?
| | Immunocompromised Host | 1 | 2008 | 201 | 0.250 |
Why?
| | Dysbiosis | 3 | 2021 | 184 | 0.250 |
Why?
| | Colon | 3 | 2021 | 304 | 0.240 |
Why?
| | Cells, Cultured | 9 | 2021 | 4112 | 0.240 |
Why?
| | Mice | 25 | 2025 | 18266 | 0.240 |
Why?
| | Th2 Cells | 2 | 2005 | 179 | 0.240 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 6 | 0.240 |
Why?
| | Lymphangioma | 1 | 2006 | 9 | 0.240 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 225 | 0.240 |
Why?
| | Time Factors | 12 | 2024 | 7079 | 0.240 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 208 | 0.240 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 24 | 0.230 |
Why?
| | Population Surveillance | 2 | 2021 | 477 | 0.230 |
Why?
| | Transplantation Immunology | 1 | 2005 | 28 | 0.230 |
Why?
| | Ecotype | 1 | 2025 | 15 | 0.230 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 371 | 0.230 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 89 | 0.230 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1244 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 79 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 41 | 0.220 |
Why?
| | Exome | 2 | 2017 | 232 | 0.220 |
Why?
| | Signal Transduction | 10 | 2025 | 5234 | 0.220 |
Why?
| | Mentors | 1 | 2007 | 215 | 0.220 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 14 | 0.220 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 50 | 0.220 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 122 | 0.220 |
Why?
| | Catheter Ablation | 4 | 2016 | 355 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 94 | 0.220 |
Why?
| | Computational Biology | 3 | 2025 | 675 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 14 | 0.210 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 112 | 0.210 |
Why?
| | Radiation Injuries | 2 | 2021 | 149 | 0.210 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 7 | 0.210 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 35 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 297 | 0.210 |
Why?
| | Virus Replication | 5 | 2017 | 525 | 0.210 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.210 |
Why?
| | Th1 Cells | 2 | 2019 | 138 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2005 | 182 | 0.210 |
Why?
| | Gastrectomy | 3 | 2025 | 162 | 0.210 |
Why?
| | Hepatectomy | 3 | 2024 | 254 | 0.210 |
Why?
| | Mice, Nude | 2 | 2024 | 665 | 0.200 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 27 | 0.200 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 245 | 0.200 |
Why?
| | Lymphocyte Count | 5 | 2017 | 166 | 0.200 |
Why?
| | Cohort Studies | 7 | 2025 | 6045 | 0.200 |
Why?
| | Carcinoma | 2 | 2006 | 225 | 0.200 |
Why?
| | Interferon-alpha | 3 | 2015 | 201 | 0.200 |
Why?
| | Ruminococcus | 2 | 2021 | 7 | 0.200 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1041 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 229 | 0.200 |
Why?
| | Flow Cytometry | 6 | 2017 | 1160 | 0.200 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.190 |
Why?
| | Immunophenotyping | 3 | 2025 | 324 | 0.190 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 44 | 0.190 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 60 | 0.190 |
Why?
| | Cannabinoids | 1 | 2025 | 181 | 0.190 |
Why?
| | Feces | 4 | 2021 | 494 | 0.190 |
Why?
| | Erythrocytes | 1 | 2009 | 749 | 0.190 |
Why?
| | Adolescent | 15 | 2019 | 22451 | 0.190 |
Why?
| | Animals | 28 | 2025 | 38030 | 0.190 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.190 |
Why?
| | Bacteria | 3 | 2018 | 766 | 0.190 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 232 | 0.190 |
Why?
| | Intestines | 2 | 2017 | 351 | 0.190 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 82 | 0.180 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 466 | 0.180 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 7 | 0.180 |
Why?
| | Specialties, Surgical | 1 | 2023 | 83 | 0.180 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 102 | 0.180 |
Why?
| | Cell Count | 2 | 2017 | 315 | 0.180 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 566 | 0.180 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 193 | 0.180 |
Why?
| | Cryosurgery | 2 | 2019 | 46 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Ampulla of Vater | 2 | 2024 | 40 | 0.180 |
Why?
| | HIV Seropositivity | 1 | 2022 | 117 | 0.180 |
Why?
| | Preoperative Care | 3 | 2018 | 375 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.170 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.170 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 77 | 0.170 |
Why?
| | Patient Selection | 3 | 2014 | 720 | 0.170 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3538 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2766 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 169 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2020 | 223 | 0.170 |
Why?
| | Critical Pathways | 1 | 2022 | 104 | 0.170 |
Why?
| | Acinetobacter | 1 | 2021 | 16 | 0.170 |
Why?
| | Germinal Center | 2 | 2025 | 67 | 0.170 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 45 | 0.170 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.160 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.160 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 180 | 0.160 |
Why?
| | Disease Progression | 2 | 2022 | 2857 | 0.160 |
Why?
| | Glucose | 3 | 2020 | 1051 | 0.160 |
Why?
| | Interleukin-2 | 5 | 2022 | 434 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 56 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 315 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 705 | 0.160 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 59 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 91 | 0.160 |
Why?
| | Risk Factors | 12 | 2024 | 10840 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2021 | 942 | 0.160 |
Why?
| | Diarrhea | 3 | 2008 | 190 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.160 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 10 | 0.160 |
Why?
| | Bacterial Translocation | 2 | 2019 | 51 | 0.160 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.160 |
Why?
| | Transcriptome | 2 | 2025 | 1066 | 0.160 |
Why?
| | Interleukins | 2 | 2019 | 247 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 40 | 0.160 |
Why?
| | Software | 1 | 2025 | 673 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 982 | 0.150 |
Why?
| | Platelet Count | 1 | 2020 | 94 | 0.150 |
Why?
| | Guidelines as Topic | 2 | 2018 | 267 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 76 | 0.150 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1132 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.150 |
Why?
| | Apoptosis | 5 | 2021 | 2436 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 218 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2021 | 2497 | 0.150 |
Why?
| | United States | 14 | 2025 | 16041 | 0.150 |
Why?
| | Dacarbazine | 4 | 2012 | 98 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 38 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 115 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 10 | 0.150 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 6 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 319 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2019 | 18 | 0.150 |
Why?
| | Palatine Tonsil | 4 | 2025 | 55 | 0.140 |
Why?
| | CD4 Antigens | 2 | 2011 | 135 | 0.140 |
Why?
| | Haploinsufficiency | 1 | 2019 | 53 | 0.140 |
Why?
| | Surgeons | 1 | 2023 | 337 | 0.140 |
Why?
| | Patient Care Planning | 2 | 2016 | 170 | 0.140 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 17 | 0.140 |
Why?
| | Stomach | 3 | 2024 | 106 | 0.140 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 211 | 0.140 |
Why?
| | Nutritional Support | 1 | 2019 | 39 | 0.140 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 48 | 0.140 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 54 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 218 | 0.140 |
Why?
| | Mastocytosis | 1 | 2019 | 15 | 0.140 |
Why?
| | Photochemotherapy | 1 | 2019 | 39 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 344 | 0.140 |
Why?
| | Intestinal Perforation | 1 | 2019 | 46 | 0.140 |
Why?
| | Decision Making | 2 | 2019 | 987 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 44 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1429 | 0.140 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 8 | 0.140 |
Why?
| | Dilatation | 1 | 2019 | 73 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 80 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 105 | 0.140 |
Why?
| | Th17 Cells | 1 | 2019 | 103 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 298 | 0.140 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 54 | 0.140 |
Why?
| | Esophagus | 1 | 2020 | 260 | 0.140 |
Why?
| | Survivors | 2 | 2015 | 521 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2411 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 568 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.130 |
Why?
| | Brachytherapy | 1 | 2019 | 132 | 0.130 |
Why?
| | Hospitals | 2 | 2021 | 730 | 0.130 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.130 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 180 | 0.130 |
Why?
| | Down-Regulation | 1 | 2020 | 612 | 0.130 |
Why?
| | HIV | 1 | 2019 | 249 | 0.130 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 21 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 40 | 0.130 |
Why?
| | Risk Assessment | 4 | 2024 | 3678 | 0.130 |
Why?
| | Viral Tropism | 1 | 2017 | 37 | 0.130 |
Why?
| | Food, Formulated | 1 | 1997 | 16 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 330 | 0.130 |
Why?
| | Liver | 4 | 2016 | 1859 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 93 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2019 | 159 | 0.130 |
Why?
| | Laser Therapy | 1 | 2019 | 146 | 0.130 |
Why?
| | Enteral Nutrition | 2 | 2010 | 212 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 145 | 0.120 |
Why?
| | Gastric Emptying | 1 | 2017 | 36 | 0.120 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2025 | 115 | 0.120 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 66 | 0.120 |
Why?
| | Arginine | 1 | 1998 | 263 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 649 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 236 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1158 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 992 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 212 | 0.120 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 820 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 49 | 0.120 |
Why?
| | Nutritional Status | 1 | 2019 | 344 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 230 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 48 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 209 | 0.120 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 69 | 0.120 |
Why?
| | Immunologic Memory | 2 | 2016 | 369 | 0.120 |
Why?
| | Bystander Effect | 1 | 2016 | 19 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 111 | 0.120 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2097 | 0.120 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 135 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 100 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.110 |
Why?
| | Mortality | 1 | 2018 | 375 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 415 | 0.110 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 104 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 845 | 0.110 |
Why?
| | Morbidity | 3 | 2023 | 317 | 0.110 |
Why?
| | Exons | 3 | 2019 | 361 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 237 | 0.110 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 56 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.110 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.110 |
Why?
| | Perioperative Care | 1 | 2018 | 229 | 0.110 |
Why?
| | Adenoma | 1 | 2017 | 209 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1223 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1754 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 319 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 538 | 0.110 |
Why?
| | Ileus | 1 | 2014 | 13 | 0.110 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.110 |
Why?
| | Postoperative Care | 1 | 1997 | 292 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 93 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4329 | 0.110 |
Why?
| | Vinblastine | 2 | 2012 | 75 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2021 | 1130 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 928 | 0.100 |
Why?
| | Viral Load | 5 | 2018 | 525 | 0.100 |
Why?
| | Endosonography | 1 | 2016 | 160 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 878 | 0.100 |
Why?
| | Ethanol | 1 | 2019 | 629 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 62 | 0.100 |
Why?
| | Quality of Life | 3 | 2019 | 3187 | 0.100 |
Why?
| | Dietary Supplements | 1 | 1998 | 586 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 56 | 0.100 |
Why?
| | Fluorouracil | 2 | 2019 | 231 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 203 | 0.100 |
Why?
| | Colectomy | 3 | 2008 | 107 | 0.100 |
Why?
| | Tumor Burden | 4 | 2022 | 326 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2674 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 889 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 369 | 0.090 |
Why?
| | RNA, Viral | 3 | 2013 | 691 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 473 | 0.090 |
Why?
| | Oligopeptides | 1 | 2014 | 264 | 0.090 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 74 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1878 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1992 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 6 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2013 | 61 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 511 | 0.090 |
Why?
| | Ablation Techniques | 1 | 2012 | 36 | 0.090 |
Why?
| | Cisplatin | 2 | 2012 | 346 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2455 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2024 | 3121 | 0.090 |
Why?
| | Biological Therapy | 1 | 2012 | 28 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2382 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 98 | 0.090 |
Why?
| | Hospital Mortality | 2 | 2016 | 1037 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 142 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 194 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 507 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 43 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 125 | 0.090 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 203 | 0.080 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.080 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 22 | 0.080 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1790 | 0.080 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 193 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 676 | 0.080 |
Why?
| | Macrophages | 2 | 2001 | 1530 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1531 | 0.080 |
Why?
| | Cell Separation | 2 | 2010 | 300 | 0.080 |
Why?
| | Extremities | 2 | 2022 | 142 | 0.080 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 314 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 189 | 0.080 |
Why?
| | Interleukin-23 | 1 | 2010 | 16 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 700 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 246 | 0.080 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 43 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 17 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 346 | 0.080 |
Why?
| | Antigens, CD | 2 | 2015 | 559 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 240 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 341 | 0.070 |
Why?
| | Viremia | 1 | 2010 | 158 | 0.070 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 142 | 0.070 |
Why?
| | Escherichia coli | 1 | 2014 | 831 | 0.070 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1500 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2015 | 774 | 0.070 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 15 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6021 | 0.070 |
Why?
| | Odds Ratio | 3 | 2019 | 1070 | 0.070 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.070 |
Why?
| | Double-Blind Method | 4 | 2014 | 2064 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2016 | 878 | 0.070 |
Why?
| | Immunoglobulins | 2 | 2023 | 162 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 851 | 0.070 |
Why?
| | Paracrine Communication | 1 | 2009 | 67 | 0.070 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 75 | 0.070 |
Why?
| | Phenotype | 5 | 2019 | 3186 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 676 | 0.070 |
Why?
| | Hyalin | 1 | 2008 | 3 | 0.070 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 29 | 0.070 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 7 | 0.070 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 155 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 402 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 613 | 0.070 |
Why?
| | Gastrostomy | 1 | 2010 | 123 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3321 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1194 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 207 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 148 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 409 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 85 | 0.070 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 81 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 959 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 268 | 0.060 |
Why?
| | Logistic Models | 4 | 2016 | 2112 | 0.060 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2024 | 3633 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2019 | 394 | 0.060 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 82 | 0.060 |
Why?
| | Career Mobility | 1 | 2007 | 68 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 582 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2008 | 219 | 0.060 |
Why?
| | Phylogeny | 2 | 2024 | 921 | 0.060 |
Why?
| | Interleukin-6 | 4 | 1999 | 782 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2019 | 319 | 0.060 |
Why?
| | Length of Stay | 3 | 2019 | 1342 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1709 | 0.060 |
Why?
| | New York | 2 | 2023 | 127 | 0.060 |
Why?
| | Laparotomy | 1 | 2007 | 109 | 0.060 |
Why?
| | Anticoagulants | 1 | 2012 | 743 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.060 |
Why?
| | Watchful Waiting | 2 | 2018 | 90 | 0.060 |
Why?
| | History, 20th Century | 1 | 2007 | 330 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 115 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2025 | 16 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2009 | 393 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1700 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 49 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 460 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 121 | 0.060 |
Why?
| | Critical Care | 1 | 2012 | 700 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 615 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 735 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 443 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 861 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 277 | 0.060 |
Why?
| | Quality Control | 1 | 2025 | 162 | 0.050 |
Why?
| | Culture Media | 1 | 2005 | 160 | 0.050 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 40 | 0.050 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 62 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 384 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 43 | 0.050 |
Why?
| | Nitric Oxide | 2 | 2001 | 883 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2008 | 284 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2007 | 305 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 39 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2005 | 2783 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 130 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 104 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 271 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 64 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 557 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 229 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1325 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 353 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 277 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 503 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 40 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 238 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 410 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 172 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 59 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 44 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 190 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 392 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 964 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 51 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 123 | 0.040 |
Why?
| | Thymus Gland | 1 | 2023 | 310 | 0.040 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 16 | 0.040 |
Why?
| | Corticosterone | 1 | 2003 | 241 | 0.040 |
Why?
| | Child | 4 | 2019 | 22638 | 0.040 |
Why?
| | Technetium | 1 | 2001 | 10 | 0.040 |
Why?
| | Injections, Intradermal | 1 | 2001 | 13 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2003 | 135 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 78 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2007 | 489 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 417 | 0.040 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 330 | 0.040 |
Why?
| | NF-kappa B | 1 | 2005 | 674 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 266 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 116 | 0.040 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.040 |
Why?
| | Leptin | 1 | 2003 | 247 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 39 | 0.040 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 446 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 78 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2001 | 182 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 238 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 355 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 10 | 0.040 |
Why?
| | Probability | 1 | 2001 | 308 | 0.040 |
Why?
| | Workload | 1 | 2002 | 169 | 0.040 |
Why?
| | Precision Medicine | 2 | 2016 | 462 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 262 | 0.040 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 342 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1323 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1647 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 60 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 17 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 721 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 210 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 423 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 501 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 994 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 122 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 692 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 88 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2446 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1033 | 0.040 |
Why?
| | Eating | 2 | 2003 | 386 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 258 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1293 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 578 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 856 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 54 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 87 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 463 | 0.040 |
Why?
| | Montana | 1 | 2018 | 18 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 57 | 0.030 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 28 | 0.030 |
Why?
| | Preoperative Period | 1 | 2019 | 150 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 698 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 356 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2019 | 234 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 90 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 727 | 0.030 |
Why?
| | Cachexia | 1 | 1999 | 74 | 0.030 |
Why?
| | Pedigree | 1 | 2019 | 507 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 530 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 192 | 0.030 |
Why?
| | Jejunostomy | 1 | 1997 | 13 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 179 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1467 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 119 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 161 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 12 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 64 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 84 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 36 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 83 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 192 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 174 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 636 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 289 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 204 | 0.030 |
Why?
| | Neck | 1 | 2017 | 107 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 216 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 268 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 427 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 29 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 337 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 222 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 973 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 441 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 33 | 0.030 |
Why?
| | Histones | 1 | 2021 | 670 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 81 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 172 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2239 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 494 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 102 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 27 | 0.030 |
Why?
| | Virion | 1 | 2015 | 112 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 187 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 67 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 466 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 489 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 141 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 746 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 429 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1720 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5875 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 595 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 536 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 1125 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 24 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 938 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 111 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 771 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 131 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 771 | 0.020 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.020 |
Why?
| | Phosphorylation | 1 | 1998 | 1717 | 0.020 |
Why?
| | Caspase 1 | 1 | 2014 | 145 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.020 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.020 |
Why?
| | Cell Lineage | 1 | 2015 | 375 | 0.020 |
Why?
| | Autoantigens | 1 | 2016 | 426 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3396 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3917 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 55 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 27 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | Inflammation | 2 | 2019 | 2915 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 83 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 364 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2013 | 181 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1581 | 0.020 |
Why?
| | International Agencies | 1 | 2012 | 30 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 53 | 0.020 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 63 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 197 | 0.020 |
Why?
| | Thoracotomy | 1 | 2012 | 87 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 84 | 0.020 |
Why?
| | Hemorrhage | 1 | 1998 | 824 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 382 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 646 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 328 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 313 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 294 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 67 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 360 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1181 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 72 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1269 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 200 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 542 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 782 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 162 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 308 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 268 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1461 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1261 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 386 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 312 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 21 | 0.020 |
Why?
| | Risk | 1 | 2013 | 917 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 327 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 598 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1102 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 36 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1318 | 0.020 |
Why?
| | Universities | 1 | 2013 | 450 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 630 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 148 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 194 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2910 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1824 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 57 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 5 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2088 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 458 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 54 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 41 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 141 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 25 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 899 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 149 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2835 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 56 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 45 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 89 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 945 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 76 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 250 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 108 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1571 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2131 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2101 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 267 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 308 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 1033 | 0.020 |
Why?
| | Swine | 1 | 2010 | 821 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 487 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 686 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 224 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 234 | 0.010 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 175 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1030 | 0.010 |
Why?
| | Whole Body Imaging | 1 | 2006 | 29 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2591 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4565 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 340 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 403 | 0.010 |
Why?
| | Radiotherapy | 1 | 2006 | 209 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2119 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10093 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 991 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 116 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 58 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 68 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 31 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 83 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4588 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 51 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 365 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 100 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 42 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 24 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 44 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 252 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 244 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 297 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 45 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 32 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 185 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 62 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2018 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3123 | 0.010 |
Why?
| | RNA | 1 | 2001 | 925 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 571 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1212 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 7217 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1491 | 0.000 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|